-

Asahi Kasei Expanding Capacity to Manufacture System Components for Clean Hydrogen

TOKYO--(BUSINESS WIRE)--Asahi Kasei has announced the official approval of new facilities at its Kawasaki Works to manufacture electrolysis system components for both alkaline water electrolysis and chlor-alkali electrolysis. Alkaline water electrolysis systems in particular are expected to enjoy significant demand growth as production of clean hydrogen becomes widespread. Through strategic allocation of resources for expansion, the company expects that hydrogen-related business will become a growing part of its Material sector over the coming years.

The new facilities will manufacture electrolysis cell frames and membranes to support two strategic business areas: alkaline water electrolysis systems used in the production of clean hydrogen, and ion-exchange membrane chlor-alkali electrolysis to produce chlorine and caustic soda. This investment strengthens vertical integration across key materials for hydrogen and chlor-alkali markets, enhancing stable supply to meet future market growth.

Initiated on December 18th, 2024, the project has been selected for financial support under the Japanese Ministry of Economy, Trade, and Industry’s “GX Supply Chain Development Program.” The new facilities enable the company to increase production and deliver cutting-edge solutions to the hydrogen, chlorine, and caustic soda markets.

Under its medium-term management plan, Asahi Kasei has positioned its alkaline water electrolysis and chlor-alkali electrolysis business under the “Growth Potential” category, viewing it as a key driver of future growth. This is part of a broader initiative to refine the Material sector through investment in revenue drivers and advancing business portfolio transformation.

In May 2025, Asahi Kasei announced the discontinuation of its MMA, CHMA, PMMA resin, and SB latex businesses, located at the Kawasaki Works. Asahi Kasei has stated that Kawasaki Works will be a key site for managing its “Energy & Infrastructure” businesses going forward.

“These new facilities integrate our long-standing expertise in chlor-alkali electrolysis with our growing capabilities in alkaline water electrolysis, enabling us to respond robustly and flexibly to both the clean hydrogen and basic chemical markets,” said Kenji Takeda, Executive Officer of Asahi Kasei for Ion-Exchange Membranes, Microza & Water Processing, and Green Solution Project Business Development. “We will continue to maximize efficiencies between these key businesses, striving to become a core player in the GX supply chain through stable supply, technological innovation, and long-term strategic growth.”

To learn more, visit https://chlor-alkali.asahi-kasei.co.jp/en/

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Healthcare, Homes, and Material. For more information, visit www.asahi-kasei.com.

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.

Contacts

North America Contact:
Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Europe Contact:
Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Asahi Kasei

TOKYO:3407

Release Summary
Asahi Kasei has announced the official approval of new facilities at its Kawasaki Works to manufacture electrolysis system components.
Release Versions

Contacts

North America Contact:
Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Europe Contact:
Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Social Media Profiles
More News From Asahi Kasei

Asahi Kasei Signs MOU With Power to Hydrogen to Accelerate Commercialization of AEM Water Electrolysis for Clean Hydrogen Production

TOKYO--(BUSINESS WIRE)--Asahi Kasei and P2H2 have signed an MOU to evaluate manufacturing scale-up and commercialization of water electrolysis systems using AEM technology....

Asahi Kasei Strengthens Carbon Footprint Transparency for Acrylonitrile Production with Independent Third-Party Verification

TOKYO--(BUSINESS WIRE)--Tongsuh Petrochemical, a subsidiary of Asahi Kasei, has obtained the “Reasonable Assurance” verification for the PCF of acrylonitrile (AN)....

Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, today announced that the U.S. Food and Drug Administration (FDA) has approved HOVILPRI® (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacy...
Back to Newsroom